Search

Displaying results 5901 - 5910 of 8009 in total
  1. Drug

    TW-37

    go.drugbank.com/drugs/DB17059
    Experimental

    TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157]

  2. Drug

    Crefmirlimab

    go.drugbank.com/drugs/DB17577
    Investigational

    Crefmirlimab is an anti-human CD8 probe targeting the CD8 antigen, for the diagnosis of various cancers.

  3. Drug

    BHT-3034

    go.drugbank.com/drugs/DB18045
    Experimental

    BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.[L48086]

  4. Drug

    XEN-D0501

    go.drugbank.com/drugs/DB18673
    Investigational

    XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.

  5. Drug

    Daphnetin

    go.drugbank.com/drugs/DB18965
    Investigational

    Daphnetin is under investigation in clinical trial NCT06329167 (Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery).

  6. Drug

    Radavirsen

    go.drugbank.com/drugs/DB15332
    Investigational

    Radavirsen is under investigation in clinical trial NCT01375985 (Safety Study of Single Administration Intravenous Treatment for Influenza).

  7. Drug

    Norleucine

    go.drugbank.com/drugs/DB15458
    Investigational

    Norleucine is under investigation in clinical trial NCT00081952 (Amino Acid Therapy for Hot Flashes in Postmenopausal Women).

  8. Drug

    Aminaphthone

    go.drugbank.com/drugs/DB13039
    Investigational

    Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac Vein Obstruction.

  9. Drug

    Iclaprim

    go.drugbank.com/drugs/DB06358
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles. It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.